Patient Journey in Advanced Gynecologic Cancers

NCT ID: NCT07015593

Last Updated: 2025-06-11

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

780 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-07-01

Study Completion Date

2026-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a mixed-methods survey study including a 2-phased sequential-explanatory design. This study is to understand the patient journey in conventional therapy for newly diagnosed stage III or IV CC or EC in China, including ①patients' treatment decision making factors and treatment experiences and ② patients' unmet needs during post-treatment surveillance.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a mixed-methods survey study including a 2-phased sequential-explanatory design: Phase 1, Qualitative interview will be done first to explore the treatment decision factors, treatment experiences and unmet needs during post treatment surveillance, to provide components and inform the quantitative data collection. Phase 2, quantitative survey to collect data on a larger scale and allow a statistical generation of the qualitative findings.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Genital Neoplasms, Female Uterine Cervical Neoplasms Endometrial Carcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

experimental group

780 patients for interview

interview

Intervention Type OTHER

30 for Qualitative interview and 750 for quantitative survey

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

interview

30 for Qualitative interview and 750 for quantitative survey

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 18 or older
* Newly diagnosed stage III or IV CC or EC
* Completed their initial conventional therapies which must include at least chemotherapy, radiotherapy or a combination between Dec. 2022 to Dec. 2024 and the therapies were within 6 months after diagnosis.
* Told by their physician that their disease is stable.
* Patients must have informed consent form (ICF) signed for the study.

Exclusion Criteria

* Previously treated with targeted biologic therapy anti-PD-1, anti-PD-L1, or anti PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor.
* Previously participated in or participating in a clinical trial.
* Patients who received another line of therapy after initial therapy.
* Unable or unwilling to provide informed consent.
* Not fluent in local language.
* Indicates or exhibits hearing difficulties, which would make a conversation challenging.
Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Tongji Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Gang Chen (101199)

Prof

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Gang Chen, PhD

Role: PRINCIPAL_INVESTIGATOR

Tongji Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Ying Zhou

Hefei, Anhui, China

Site Status

Shuzhong Yao

Guangzhou, Guangdong, China

Site Status

Gang Chen

Wuhan, Hubei, China

Site Status

Dongling Zou

Chongqing, , China

Site Status

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Gang Chen

Role: CONTACT

086-027-83662681

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Ying Zhou, PhD

Role: primary

13865901025

Shuzhong Yao, ph.D

Role: primary

086-020-87755766

Gang Chen

Role: primary

086-027-83662681

Yingjie Hu

Role: backup

086-027-83662681

Dongling Zou, ph.D

Role: primary

086-023-65301682

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

[2024]S257

Identifier Type: OTHER

Identifier Source: secondary_id

NIS103233

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Bioinformation Therapy for Gastric Cancer
NCT03350477 COMPLETED PHASE2/PHASE3